GBA Presents: THE GREEN MARKET

Boy Apple tech is good. The pre made videos they send you from your pictures is fantastic. They just sent us in the woods or the woods over the years- all shots we have taken in the woods . It was marvelous. Crap music.

They also gave us a Grandma reel and what was so impressive is it picked up masked grandma.. good software!
 
reviewing my trading history, a common theme appears. i sell too soon. i've owned shares that would have increased 50-100x, not once or twice, but many times. but i sold with 30-120% gains. so, time for more changes. LEAPs. Owning LEAPs changes the mindset. it forces one to think in terms of years instead of days and in my case, even hours. so here's my LEAP of the day: TWTR $60 call Jan 2024.
 
Supply Chain Easing-? Iceland water apparently available at my health deli .... awaiting my 3/4 size case still no large.....**** huge news!

Unconventional I wonder if you could set up a tracking portfolio sort of an LEAP IRA? At one time I had this going we were buying and selling so much stuff that one account was just buy-Hold. Hell or high water. Don't even look. And there you would get your 300+% gainers.
 
unconventional wisdom said:
reviewing my trading history, a common theme appears. i sell too soon. i've owned shares that would have increased 50-100x, not once or twice, but many times. but i sold with 30-120% gains. so, time for more changes. LEAPs. Owning LEAPs changes the mindset. it forces one to think in terms of years instead of days and in my case, even hours. so here's my LEAP of the day: TWTR $60 call Jan 2024.
More...


I'm also using this type of strategy. Currently owning a lot of pfe calls 60. (not 'leaps' anymore btw, march 22)

I try to sell shortdated calls - around atm - against them when I think they are overstretched to mitigate the costs of the premium, and (hopefully) catch a countertrend part of the move.

How do pick your strike for this? Wouldn't the 55 strike be better 'value' for example? Ofcourse this should all be priced in with current information, but a quick look for the last prices gave 9.20(55) and 9.90 (60) so I would personally go for the 55 strike (but there is no 'big analysis' behind this).
 
stonedinvestor said:
Supply Chain Easing-? Iceland water apparently available at my health deli .... awaiting my 3/4 size case still no large.....**** huge news!

Unconventional I wonder if you could set up a tracking portfolio sort of an LEAP IRA? At one time I had this going we were buying and selling so much stuff that one account was just buy-Hold. Hell or high water. Don't even look. And there you would get your 300+% gainers.
More...

It really is sometimes crazy to see the returns if you just .... sat on your hands. Had this experience a lot more than I like to admit :banghead:
 
Another idea:

Using twtr puts 16 sept 22:
- 55 strike
+ 45 strike
- 35 strike

Should go for debit/credit around 0. Basically capping the upside and trade it for a cushion till 35 for it. I personally do not like capping upside, but it may be usefull for someone here.
 
I can't figure this one out, but there was a ton of call buying on the Dec and Jan ALDX calls today. Most at the ask.
But the stock tanked. There's no new news since the last time we discussed it a week or two ago.
Someone also bought quite a few $5 puts for cheap. A hedge? Beats me.
Something's brewing though.
$ALDX -----> $7.16 (-6.77%)


Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company’s lead product candidate is reproxalap, an ophthalmic solution, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It also develops ADX-2191, a dihydrofolate reductase inhibitor which is in phase 3 for the prevention of proliferative vitreoretinopathy, and phase II clinical trial for the treatment of primary vitreoretinal lymphoma. The company’s portfolio also consists of ADX-1612, a small molecule heat shock protein 90 (Hsp90) inhibitor for the treatment of lymphoproliferative diseases and covid-19; and reactive aldehyde species that are pro-inflammatory (RASP) scavengers, such as ADX-629 for treating autoimmune diseases, allergy, and covid-19, as well as ADX-103 for the treatment of retinal diseases. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is headquartered in Lexington, Massachusetts.


stonedinvestor said:
Van ALDX will be reporting trials in the 4th QTR. I think you want a fresher idea than that and come back to this idea.... Start with OCUL
More...
 
vanzandt said:
I can't figure this one out, but there was a ton of call buying on the Dec and Jan ALDX calls today. Most at the ask.
But the stock tanked. There's no new news since the last time we discussed it a week or two ago.
Someone also bought quite a few $5 puts for cheap. A hedge? Beats me.
Something's brewing though.
$ALDX -----> $7.16 (-6.77%)


Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company’s lead product candidate is reproxalap, an ophthalmic solution, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It also develops ADX-2191, a dihydrofolate reductase inhibitor which is in phase 3 for the prevention of proliferative vitreoretinopathy, and phase II clinical trial for the treatment of primary vitreoretinal lymphoma. The company’s portfolio also consists of ADX-1612, a small molecule heat shock protein 90 (Hsp90) inhibitor for the treatment of lymphoproliferative diseases and covid-19; and reactive aldehyde species that are pro-inflammatory (RASP) scavengers, such as ADX-629 for treating autoimmune diseases, allergy, and covid-19, as well as ADX-103 for the treatment of retinal diseases. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is headquartered in Lexington, Massachusetts.
More...


We'll have to see what tomorrow's OI is on these.





upload_2021-11-29_20-18-33.jpeg
 
You must log in or register to reply here.
Back
Top